Results 131 to 140 of about 9,615 (165)
Ibrutinib as first-line therapy for mantle cell lymphoma: a multicenter, real-world UK study
During the COVID-19 pandemic, ibrutinib with or without rituximab was approved in England for initial treatment of mantle cell lymphoma (MCL) instead of immunochemotherapy. Because limited data are available in this setting, we conducted an observational
Walter, Harriet
core +1 more source
Pirtobrutinib in Richter syndrome: Outcomes from the named patient programme in Italy
British Journal of Haematology, Volume 209, Issue 5, Page 2302-2306, November 2026.
Isacco Ferrarini +19 more
wiley +1 more source
Ibrutinib in chronic lymphocytic leukemia and B cell malignancies
inhibits signaling and adhesion in response to CXCL12 and CXCL13 Th e phase 1 study of ibrutinib in hematologic malignancies enrolled patients with any B cell lymphoma including CLL into fi ve cohorts of punctuated dosing (28 days on, 7 days off ) and ...
core
The role of ibrutinib in Waldenström macroglobulinemia
Introduction: Waldenström macroglobulinemia (WM) is an uncommon incurable B-cell lymphoma characterized by the presence lymphoplasmacytic cells in the bone marrow.
Gavriatopoulou, M. +3 more
core
Some of the next articles are maybe not open access.
Related searches:
Related searches:
Reactions Weekly, 2018
Abnormal B-cell receptor (BCR) signalling is a key mechanism of disease progression in B-cell malignancy. Bruton's tyrosine kinase (BTK) has a pivotal role in BCR signalling. Ibrutinib (PCI-32765) is a small molecule which serves as a covalent irreversible inhibitor of BTK. It is characterized by high selectivity for BTK and high potency.
Andriani, Charalambous +2 more
+8 more sources
Abnormal B-cell receptor (BCR) signalling is a key mechanism of disease progression in B-cell malignancy. Bruton's tyrosine kinase (BTK) has a pivotal role in BCR signalling. Ibrutinib (PCI-32765) is a small molecule which serves as a covalent irreversible inhibitor of BTK. It is characterized by high selectivity for BTK and high potency.
Andriani, Charalambous +2 more
+8 more sources
2014
Abnormal B-cell receptor (BCR) signaling is a key mechanism of disease progression in B-cell malignancy. Bruton's tyrosine kinase (BTK) has a pivotal role in BCR signaling. Ibrutinib (PCI-32765) is a novel agent which serves as a covalent irreversible inhibitor of BTK. It is characterized by high selectivity for BTK and high potency.
Mark-Alexander, Schwarzbich +1 more
openaire +2 more sources
Abnormal B-cell receptor (BCR) signaling is a key mechanism of disease progression in B-cell malignancy. Bruton's tyrosine kinase (BTK) has a pivotal role in BCR signaling. Ibrutinib (PCI-32765) is a novel agent which serves as a covalent irreversible inhibitor of BTK. It is characterized by high selectivity for BTK and high potency.
Mark-Alexander, Schwarzbich +1 more
openaire +2 more sources

